CATEGORIES

Pharmaceutics

LATEST

TRENDING

EDITORS CHOICE

Is Silmitasertib the Covid-19 Treatment Breakthrough We’ve Been Waiting for?

Within 24 hours of the first dose of Silmitasertib the patient showed significant clinical improvement and the oxygen requirement was weaned to room air. The patient was discharged from the hospital five days after starting Silmitasertib.

Arjuna Unveils New Botanical Analgesic Blend

The three botanicals are synergistically blended with a unique proprietary technology to provide fast relief of acute musculoskeletal pain.

Busted! Explaining Common Vaccine Myths

Here are some of the most common myths and the reasons why you shouldn’t believe them.

SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults Approved

SPRAVATO® (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.